Coverage Initiation Report Focuses on Oramed Pharmaceuticals
(firmenpresse) - NEW YORK, NY -- (Marketwired) -- 11/11/14 -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) is the subject of a new in-depth initiation coverage repot by Acceleron Equity Research.
Interested investor may get more information and a copy of the coverage report at:
On November 3, 2014 ORMP announced very favorable top-line results from a Phase 2a trial for its oral insulin capsule in ORMD-0801 for Type 1 diabetes, addressing the multi-billion dollar diabetes market.
ORMP''s unique Protein Oral Delivery (POD™) technology is a breakthrough in medical science that enables small proteins to travel through the gastrointestinal tract, via the liver, and into the bloodstream to treat a broad number of indications including diabetes.
POD technology addresses a market of roughly $50 billion worth of drugs and vaccines that are currently delivered via injections. This includes diabetes, the first indication pursued by OMRP, a market where $20 billion worth insulin was sold globally in 2013.
The Company''s ORMD-0801 oral insulin capsule has the potential to create a new paradigm in the treatment of Type 2 diabetes by treating the disease at an earlier stage, thereby slowing its progression. Having completed a successful FDA Phase 2a trial in Type 2 diabetes, ORMP is now planning its Phase 2b trial for Type 2 diabetes.
ORMD-0901, an oral GLP-1 analog, addressing an annual $2 billion market is expected to enter Phase 1b trials in Israel by the end of 2014. In Q3 of 2013 ORMP submitted a Pre-IND package to the U.S. FDA. ORMP expects to begin a Phase II multi-center study for ORMD-0901 in Q3-2015.
Acceleron is a market intelligence service that focuses on identifying and analyzing technically-complicated companies and equities. Acceleron offers a subscription model product to investors and funds with an emphasis in the emerging markets.
Media Contact:
Mike Morhamus
Acceleron Equity Research
855-216-8786
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 11.11.2014 - 07:45 Uhr
Sprache: Deutsch
News-ID 1317281
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
NEW YORK, NY
Phone:
Kategorie:
Biotech
Anmerkungen:
Diese Pressemitteilung wurde bisher 102 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Coverage Initiation Report Focuses on Oramed Pharmaceuticals
"
steht unter der journalistisch-redaktionellen Verantwortung von
Oramed Pharmaceuticals (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
